Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7346929 | 0.88 | AKR1B1 (0.56) | MAPTALDH1A1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL13870592 | 0.83 | ALDH1A1 (0.45) | MAPTALDH1A1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL9749938 | 0.81 | MAPT (0.59) | MAPTALDH1A1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL9749948 | 0.81 | MAPT (0.59) | MAPTALDH1A1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL86392 | 0.78 | MAPT (0.67) | MAPTALDH1A1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL29375440 | 0.78 | MAPT (0.67) | MAPTALDH1A1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL7820863 | 0.78 | ALDH1A1 (0.68) | MAPTALDH1A1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL8797878 | 0.78 | MAPT (0.68) | MAPTALDH1A1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL655741 | 0.78 | MAPT (1.00) | MAPTALDH1A1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL8797223 | 0.78 | MAPT (0.68) | MAPTALDH1A1RAB9ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524864-B2 | Methods of treating sleep disorders | HYPNION, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524864-B2 | Methods of treating sleep disorders | HYPNION, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7482460-B2 | Doxepin analogs and methods of use thereof | HYPNION, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482460-B2 | Doxepin analogs and methods of use thereof | HYPNION, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7411069-B2 | Doxepin analogs and methods of use thereof | HYPNION, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-7411069-B2 | Doxepin analogs and methods of use thereof | HYPNION, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-7355042-B2 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7355042-B2 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7326721-B2 | Doxepin analogs and methods of use thereof | HYPNION, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326721-B2 | Doxepin analogs and methods of use thereof | HYPNION, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7317026-B2 | Sleep disorders; side effect reduction ; antihistamine antagonist | HYPNION, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7317026-B2 | Sleep disorders; side effect reduction ; antihistamine antagonist | HYPNION, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7189757-B2 | Treatment of sleep disorders using CNS target modulators | HYPNION, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189757-B2 | Treatment of sleep disorders using CNS target modulators | HYPNION, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | UBE INDUSTRIES, LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1254897-A1 | TRICYCLIC COMPOUNDS | Ube Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
| EP-0069810-B1 | NOVEL DIBENZOXEPINS, THEIR PREPARATION, COMPOSITIONS CONTAINING THEM AND THE USE OF DIBENZOXEPINS IN THE TREATMENT OF ALLERGIC CONDITIONS | MERCK & CO. INC. (US) | 1986-12-03 | — | — | EP | disclosed |
| EP-0188802-A2 | Dibenz (b,e) oxepin derivative and antiallergic agent | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1986-07-30 | — | — | EP | disclosed |
| US-4282365-A | Dibenz[b,e]oxepin compounds | MERCK & CO., INC. (US) | 1981-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | CYSLTR2, CYSLTR1, LTC4S | MAPT 4812/4885ALDH1A1 921/4885RAB9A 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.